| Literature DB >> 34644115 |
Ana Nikolic1,2,3, Divya Singhal1,2,3, Katrina Ellestad1,2,3, Michael Johnston1,2,3, Yaoqing Shen4,5, Aaron Gillmor1,2,3, Sorana Morrissy1,2,3, J Gregory Cairncross1,6, Steven Jones4,5, Mathieu Lupien7,8,9, Jennifer A Chan1,2,6, Paola Neri1,6, Nizar Bahlis1,6, Marco Gallo1,2,3.
Abstract
Single-cell epigenomic assays have tremendous potential to illuminate mechanisms of transcriptional control in functionally diverse cancer cell populations. However, application of these techniques to clinical tumor specimens has been hampered by the current inability to distinguish malignant from nonmalignant cells, which potently confounds data analysis and interpretation. Here, we describe Copy-scAT, an R package that uses single-cell epigenomic data to infer copy number variants (CNVs) that define cancer cells. Copy-scAT enables studies of subclonal chromatin dynamics in complex tumors like glioblastoma. By deploying Copy-scAT, we uncovered potent influences of genetics on chromatin accessibility profiles in individual subclones. Consequently, some genetic subclones were predisposed to acquire stem-like or more differentiated molecular phenotypes, reminiscent of developmental paradigms. Copy-scAT is ideal for studies of the relationships between genetics and epigenetics in malignancies with high levels of intratumoral heterogeneity and to investigate how cancer cells interface with their microenvironment.Entities:
Year: 2021 PMID: 34644115 PMCID: PMC8514091 DOI: 10.1126/sciadv.abg6045
Source DB: PubMed Journal: Sci Adv ISSN: 2375-2548 Impact factor: 14.136
Fig. 1.Copy-scAT workflow.
(A) Copy-scAT accepts barcode-fragment matrices generated by Cell Ranger (10x Genomics) as input.(B) Large peaks in normalized coverage matrices can be used to infer focal CNVs. ecDNA, extrachromosomal DNA. (C) Normalized matrices can be used to infer segmental and chromosome arm-level CNVs. (D) Example of chromosome arm-level CNV (chromosome 10p loss) called by Copy-scAT. (E) Consensus clustering is used to finalize cell assignment.
Fig. 2.Benchmarking of Copy-scAT with three methods involving clinical samples from three distinct malignancies.
(A) Banked cryopreseved aGBM samples were used for both scATAC and WGS. Nuclei were isolated from the samples, mixed, and used for both scATAC and WGS. (B to D) Percent of chromosome arm-level gains, chromosome arm-level losses, and focal amplifications detected in aGBM samples identified using both methods versus CNVs detected by scATAC or WGS alone. (E) Banked frozen pGBM samples were used for both scATAC and WGS. (F and G) Number of chromosome arm-level gains and losses detected in pGBM samples identified using both methods versus total numbers of gains detected by scATAC or WGS. (H) Fresh MM samples were used for both scATAC and 10x scCNV DNA analysis. (I and J) Number of chromosome arm-level gains and losses detected by both methods versus total numbers of gains detected by scATAC or 10x scCNV analysis. (K) Overview of raw transformed z-score profiles for four aGBM samples.
Fig. 3.Detection of CNVs and identification of neoplastic clones with Copy-scAT.
(A) Chromosome 7p gain in an aGBM sample (CGY4349). (B) Chromosome 7q gain in an aGBM sample. (C) Chromosome 10p loss in an aGBM sample. (D) MDM4 amplification in an aGBM sample (CGY4349). Amplified cells, orange; nonamplified cells, gray. (E) PDGFRA amplification in an aGBM sample (CGY4349). Amplified cells, orange; nonamplified cells, gray. (F) EGFR amplification in an aGBM sample (CGY4349). Amplified cells, orange; nonamplified cells, gray. (G) ChromVAR activity score for the ASCL1 motif. (H) ChromVAR activity score for the IKZF1 motif. (I) ChromVAR activity score for the FOXG1 motif.
Fig. 4.Subclonal genetics influences clustering of scATAC-seq data.
(A to C) CNVs in aGBM CGY4218 segregate within specific scATAC clusters. (D and E) PDGFRA-amplified cells cluster together in aGBM CGY4349. (F) Diagram summarizing our strategy to remove CNVs from clustering of scATAC data. All chromosomes or regions with putative CNVs were removed from downstream analyses, and cells were reclustered. (G) Reclustering of (D) following removal of chromosomes and regions affected by CNVs in CGY4349. (H) Distribution of PDGFRA-amplified cells following reclustering. (I) Cluster assignments of cells in CGY4349 (aGBM specimen) before and after removal of CNV-containing regions (purple, PDGFRA-amplified cells).
Fig. 5.Subclonal genetic alterations predispose cells to adopt developmental chromatin states.
(A) Cells were clustered on the basis of scATAC ChromVAR motif scores and then shaded on the basis of the presence of one, two, or three copies of chromosome 1p. NA, not available. (B) Schematic of method used to determine putative cycling cells. (C) Cells were shaded on the basis of their predicted cycling properties. (D) Data shown in (A) projected onto pseudotime. The resulting three branches are populated preferentially by cells with gain or loss of chromosome 1p, respectively. (E) Proliferation status as shown in (B), overlaid onto pseudotime. (F) Tumor cells with chromosome 1p gain show greater proportions of proliferative cells (statistics, chi-square test). (G) Scaled chromatin accessibility at binding motifs for OLIG2 and HOXA2, two TFs associated with stemness. (H) Scaled chromatin accessibility at binding motifs for RFX2 and NFIX, two TFs associated with progenitor-like phenotypes. (I) Scaled chromatin accessibility at binding motifs for RARA::RXRA and signal transducers and activators of transcription 3 (STAT3), two TFs associated with differentiated phenotypes. (J) Enrichment plot for motif z scores for OLIG2 and HOXA2. (K) Enrichment plot for motif z scores for RFX and NFIX. (L) Enrichment plot for motif z scores for RARA::RXRA and STAT3. P values were calculated by Kruskal-Wallis test.